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A100 Abstracts
from PQRI and HEDIS 2010 requirements; pharmacy measures included 14 PQA 
measures being tested for these diseases. Measures were reviewed to identify: 1) type 
(process/outcome) 2) constructs; and 3) data requirements (pharmacy, medical, labora-
tory). RESULTS: Forty-eight measures were included (13 HEDIS, 21 PQRI, 14 PQA). 
HEDIS and PQRI measures for diabetes and dyslipidemia emphasize outcomes 
(achievement of Hgb A1c and LDL goals) and % receiving recommended screenings, 
while PQA measures emphasize process (adherence as gaps in therapy and proportion 
of days covered), excessive doses of diabetes medications, and suboptimal treatment 
(% on diabetes prescription without an ACEI or ARB). HEDIS, PQRI, and PQA 
measures for asthma assess use of controller medications, though 1 PQA measure also 
assesses overuse of beta agonists. Differences in the types and constructs of measures 
suggest opportunities for alignment. A bi-level framework that employs reporting 
pharmacy measures among patients who have not met the physician measure may 
facilitate a team approach for diabetes and hypertension quality, though this 
would only be feasible for organizations holding both medical and pharmacy data. 
CONCLUSIONS: Medication quality measures are of increasing importance, yet 
available physician and pharmacy measures differ. Findings suggest that testing a 
bi-level framework for diabetes and hypertension pharmacy quality measurement 
would be worthwhile.
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OBJECTIVES: Authorized generics (AGs) are products manufactured by a patent 
holder but marketed by a subsidiary or a third party company. AGs might increase 
competition and reduce generic prices when launched during the 180-day exclusivity 
period of an independent generic(s) (IGs). AGs launched during IG exclusivity might 
also present a long-term disadvantage to consumers by delaying timely entry of gener-
ics. The objectives of this study were: 1) to determine the trend in market share of 
AGs during the ﬁrst six months for drugs launched with a ﬁrst-ﬁler(s) 180-day exclu-
sivity; 2) to determine the trend in market share of AGs for the ﬁrst six months for 
drugs launched without ﬁrst-ﬁler(s) exclusivity. METHODS: Five drugs were selected 
as cases to assess the effect of AGs launched during the exclusivity of IGs on market 
share of the brand and generic products. Each product selected had three subcatego-
ries: a brand name drug, an AG and at least one IG on the market. The unit of analysis 
was the number of prescriptions dispensed, without regard to the dispensed quantity. 
RESULTS: At the end of the ﬁrst year, market shares of AGs launched with the 
exclusivity of an IG in the cases of Zocor®, Proscar® and Norvasc® were 37%, 52% 
and 49%, respectively. Meanwhile, market shares of AGs launched without the 
exclusivity of an IG in the cases of Arava® and Ambien® were 21% and 14%, 
respectively. CONCLUSIONS: AGs launched during IG exclusivity dominated the 
market and had the largest market share when compared to any other single market 
participant for the case. AGs launched during IG exclusivity obtain a dominant market 
share position and in the long run might discourage IG companies from timely generic 
introductions. Policy limiting the entry of AGs during the exclusivity of IG exclusivity 
might prevent delayed generic entry.
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DESCRIPTION AND EVALUATION OF THE KNOWLEDGE OF THE 
BRASILIA POPULATION FOR THE POLITICS OF ECONOMIC MEDICINE 
REGULATION IN BRAZIL
Araujo MAM, Rebelo FM, Freitas PC, Alaver RT
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OBJECTIVES: The primary objective was to evaluate the knowledge of the drugstore 
consumers from Brasilia and workers of ANVISA, for the regulation of prices of 
medicines. The speciﬁc objectives were to assess the knowledge of the populations on 
PMC, different price of generic medicines, estimate monthly expenses of the two 
samples and a preliminary comparative analysis between the two samples. METHODS: 
The study developed is a cross descriptive and analytical study. Based in the applica-
tion of different questionnaires for to assess the knowledge about regulation of prices 
of medicines and consumption habits of consumers interviewed in the door of the 
drugstore and workers of ANVISA. The research was conducted by sampling accord-
ing to the location of the drugstore and in accordance with the area of capacity in the 
workers of ANVISA. RESULTS: there were interviewed 105 consumers in drugstores 
and 140 workers of ANVISA. When asked about the existence of market regulation 
of drugs, 51.43% and 87.14% of drug users and employees of ANVISA, respectively, 
said there is regulation of these products. About the PMC, the knowledge was 20.00% 
of respondents in pharmacies and 57.86% of the employees of ANVISA. Despite of 
the relative knowledge of PMC, only 01 of the respondents knew where consumers 
search the PMC, and the employees of ANVISA, 29 knew the sources of research. 
Although the poor knowledge on the regulation of prices, 84.76% of consumers 
interviewed considered this activity exerted by the government as important. CON-
CLUSIONS: Although the population consider important that the prices of medicines 
are regulated by the government, the knowledge of the regulation is small, even on 
the tools of consumer protection.
PHP100
INDEPENDENT RETAIL PHARMACY ATTRIBUTES, INSURER 
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OBJECTIVES: 1) To examine whether small individual provider attributes affects 
reimbursement between insurer and independent retail pharmacies, and 2) to under-
stand the implication of our results on the potential impact of the proposed community 
pharmacy collective bargaining law. METHODS: Data were collected and compiled 
from four sources: a national mail survey to independent pharmacies, National 
Council for Prescription Drug Programs Pharmacy database, 2000 U.S. Census and 
2006 Economic Census data. Pharmacy bargaining power was calculated using the 
costs, cash prices and reimbursement rates of a brand name drug Lipitol and a generic 
drug Lisinopril acquired from the survey. Key independent variables include individual 
pharmacy attributes and local market structure measures. RESULTS: Reimbursements 
varied substantially across pharmacies. For Lipitor, best reputation (β = 0.101), easiest 
accessibility (β = 0.067), pharmacy ownership concentration index (β = 0.104) and 
area per capita income (β = −0.165) are signiﬁcant predictors of pharmacy bargaining 
power. For Lisinopril, only easiest access (β = 0.082) and per capita income (β = 
−0.068) are found to be signiﬁcant. CONCLUSIONS: Pharmacies with the best repu-
tation, easiest access and facing less competition in its market receive higher reimburse-
ment rates for brand name drugs. An independent pharmacy with the best reputation 
and easiest access and with average dispensing volume would receive $167,688 more 
in reimbursement a year than a pharmacy that doesn’t have the best reputation and 
easiest access. Our results suggest that the current third party contracting practice 
rewards pharmacies with favorable attributes with higher reimbursements. Our results 
also imply that a collective bargaining law for independent pharmacies is likely to 
beneﬁt those pharmacies currently receiving below average reimbursement rates due 
to weaker market positions, and would have the potential effect of raising costs and 
removing incentives for pharmacies to maintain the attributes that are valuable to 
customers.
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OBJECTIVES: To evaluate treatment group differences in clinician reported ease of 
use between Fibrin Pad (FP) and Surgicel for hemostasis in subjects with mild or 
moderate bleeding using a novel survey tool. METHODS: The Ease of Use Question-
naire (EUQ) was used as part of a randomized, controlled, clinical study of FP versus 
Surgicel for intra-operative hemostasis. Subjects were randomized at 11 institutions 
with a 2:1 FP to Surgicel ratio. Additional subjects were enrolled in the non-random-
ized phase and treated with FP. Subjects were stratiﬁed according to bleeding severity. 
Up to the ﬁrst three subjects completed the EUQ at each institution. The ﬁnal sample 
was N = 20 FP and N = 8 Surgicel (randomized) and N = 2 FP (non-randomized). 
The EUQ is a 19-item instrument evaluating clinicians’ perceptions and preferences 
for hemostasis products on ﬁve subscales (Ease of Use, Satisfaction with Product 
Properties and Efﬁciency, Conﬁdence in Efﬁcacy, Global Conﬁdence, and Global 
Satisfaction).1 Differences in ease of use between treatment groups were evaluated 
using ﬁve ANCOVA models where subscale scores were the dependent variables, 
treatment group was the independent variable, and severity of bleeding was controlled 
for as the covariate. RESULTS: Mean subscale scores for Conﬁdence in Efﬁcacy (FP 
= 4.70 vs. S = 3.50), Global Conﬁdence (FP = 4.70 vs. S = 4.13) and Global Satisfac-
tion (FP = 4.85 vs. S = 4.04) were signiﬁcantly higher for the FP group as compared 
to the Surgicel group (all p < 0.05). Mean subscales scores for Ease of Use (FP = 4.82 
vs. S = 4.66) and Satisfaction (FP = 4.71 vs. S = 4.34) were higher for the FP group, 
but non-signiﬁcant. CONCLUSIONS: Physicians reported higher ease of use, satisfac-
tion, and global conﬁdence with FP for hemostasis in mild to moderate bleeding. 
Non-signiﬁcant results in the Ease of Use and Satisfaction subscales likely resulted 
from small sample sizes. Future studies should evaluate ease of use in the full range 
of bleeding severities and larger sample sizes.
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ADVANCING THE EVIDENCE BASE FOR ORTHOTICS AND 
PROSTHETICS
Mohandas A, Thompson E, Goldfarb N
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OBJECTIVES: Limited information is currently available regarding outcomes related 
to orthotics and prosthetics (O&P). Rapidly emerging technologies in the O&P ﬁeld 
have increased the need for comparative effectiveness studies examining clinical, 
humanistic, and economic outcomes. The objective of this project was to establish and 
pilot test a patient registry for outcomes assessment. METHODS: A web-based survey 
system combining input from both O&P providers and their patients was developed 
and pilot-tested among nine O&P clinics across the country. The providers entered 
